Syndrome of the month

Pyruvate dehydrogenase deficiency

G K Brown, L J Otero, M LeGris, R M Brown

Pyruvate dehydrogenase (PDH) deficiency is one of the most common of the defined genetic defects of mitochondrial energy metabolism. It is also one of the few X linked diseases in which a high proportion of heterozygous females manifest severe symptoms and the pathogenesis is understood. PDH deficiency is an extremely heterogeneous condition, both in clinical presentation and the severity of the biochemical abnormality, with a clinical spectrum ranging from fatal lactic acidosis in the newborn period to a chronic neurodegenerative condition with gross structural abnormalities in the central nervous system. The chronic neurological form of PDH deficiency represents an excellent illustration of the principle that structural defects, and in particular developmental anomalies, do not preclude a diagnosis of metabolic disease.

The biochemical abnormalities reflect the role of the PDH complex in normal energy metabolism. The enzyme catalyses the conversion of pyruvate (derived mainly from glucose) to acetyl coenzyme A, a key regulatory step in the central pathways of energy metabolism in the mitochondrion (fig 1). PDH is a multi-enzyme complex composed of multiple copies of nine different gene products. Five of the subunits make up the three enzyme activities which are involved in the conversion of pyruvate to acetyl CoA. The others constitute specific regulatory components, a kinase and phosphatase, which control the activity of the entire complex (fig 2).

The level of activity of the PDH complex determines the balance between the use of alternative energy substrates and, in some tissues, the enzyme operates at near maximal rate. Consequently, relatively modest reductions in activity may lead to accumulation of pyruvate and, more importantly, lactic acid. Although the PDH complex plays an important role in all metabolically active tissues, it plays a critical role in the brain under normal conditions. This is because the brain usually obtains all of its energy from the aerobic oxidation of glucose. All patients with PDH deficiency have some degree of neurological impairment.

Clinical presentations
The following description of the features of PDH deficiency is based on our own experience of over 40 cases, and other published reports. Several hundred patients have now been described. PDH deficiency has a significant effect on fetal development and this may become apparent during late pregnancy with poor fetal weight gain and falling maternal urinary oestriol levels. Delivery may be complicated and the babies may have low Apgar scores. A low birth weight is very common. It has been suggested that there is a characteristic dysmorphic appearance associated with PDH deficiency, with a narrow head, frontal bossing, wide nasal bridge, long philtrum and flared nostrils, but this is not seen in all cases and is not specific to the disease. Other congenital malformations (simian creases, short neck, slight shortening of the limbs, flexion contractures, pes cavus, talipes, ventricular septal defect, and hydronephrosis) have been recorded in a few cases.

Patients with PDH deficiency typically develop symptoms soon after birth. In general, there are two forms of presentation, metabolic and neurological, and these occur at approximately equal frequency. The metabolic form presents as severe lactic acidosis with blood lactate concentration often greater than 10 mmol/l. The lactic acidosis is almost always refractory to treatment and many of these patients die within the newborn period. In a very few cases, the lactic acidosis has been reported to respond to high doses of thiamine. A small number of patients with profound lactic acidosis have also
had significant hyperammonaemia in the newborn period. Patients with neurological presentation are hypotonic, feed poorly, and are lethargic. Later, they develop seizures, either tonic/clonic convulsions or typical infantile spasms. This form of the disease usually progresses to profound mental retardation, microcephaly, blindness, and spasticity with secondary contractures. Long term survival is possible and several of these patients have reached their teens.

Between these two extremes, there is a continuous spectrum of intermediate forms. When the metabolic abnormalities are less severe, the onset may be delayed until later in infancy and the clinical course is often characterised by intermittent episodes of lactic acidosis, often precipitated by intercurrent illness, and associated with cerebellar ataxia. A number of the patients with primarily neurological symptoms fit into the category of Leigh's syndrome, a subacute neurodegenerative disease with prominent brain stem features.

Although PDH deficiency occurs with equal frequency in males and females, the presentation of the disease differs between the sexes. The metabolic end of the spectrum, especially the severe neonatal lactic acidosis, predominates in males and the chronic neurological form is much more common in females. Neurological disease in males often manifests as Leigh's syndrome. In patients with prominent neurological symptoms, there are often major structural defects in the brain (fig 3) and metabolic abnormalities may be absent or minimal. In these cases, a possible diagnosis of PDH deficiency may be overlooked.

**Neuropathology**

Structural abnormalities in the brain are one of the most striking aspects of PDH deficiency. The lesions are generated by two different pathological processes, degenerative change and developmental malformation, and are seen most clearly in patients with the chronic neurological form of the disease. These patients typically have marked cerebral atrophy and ventricular dilatation (fig 3), sometimes to the extent that a diagnosis of hydranencephaly is considered. In addition to the destructive changes, there is a characteristic pattern of developmental anomalies which includes complete or partial absence of the corpus callosum, absence of the medullary pyramids, and abnormal and ectopic inferior olives. Patients presenting as Leigh's syndrome have the characteristic pathological changes of symmetrical cystic lesions and gliosis in the basal ganglia and brain stem, accompanied by capillary proliferation. Surprisingly, patients with early onset severe lactic acidosis, particularly males, may have remarkably little neuropathology. In some there is generalised hypomyelination, others have small cystic lesions and gliosis in the cortex, basal ganglia, brain stem, or cerebellum.

**Diagnosis**

The diagnosis of PDH deficiency should be considered in all patients with early onset neurological disease, especially if associated with structural abnormalities in the brain and a lactic acidosis for which there is no other apparent cause. Many of the neuropathological changes may be detected by ultrasound in the
newborn period or with CT or MRI scans of the brain. When the blood lactate is not significantly raised, an important clue to the diagnosis is selective elevation of the lactate concentration in cerebrospinal fluid. If proton magnetic resonance spectroscopy of the brain is available, it can be used to show accumulation of lactate in the central nervous system. The differential diagnosis of primary lactic acidosis includes other defects of pyruvate metabolism (such as pyruvate carboxylase deficiency), defects of gluconeogenesis, and disorders of the mitochondrial electron transport chain. Isolated accumulation of lactic acid is the common metabolic abnormality in all of these conditions, although hypoglycaemia, especially after fasting, may be a prominent feature of the defects of gluconeogenesis. Early onset mitochondrial disease often involves multiple tissues including muscle, heart, liver, and kidney. These organs are not involved in PDH deficiency as they are able to use substrates other than glucose for energy. In all of these conditions, the diagnosis is based on specific biochemical investigations.

Specific enzyme assays have been designed which allow the measurement both of the overall maximal PDH activity and that of the individual components of the multi-subunit complex. The great majority of patients suffering from PDH deficiency are found to be defective in the E1 enzyme but abnormalities have also been detected in the E2 and E3 components. Results of these assays show a wide range in residual enzyme activity and a poor correlation with clinical presentation, although, in general, patients with lower residual activity present earlier and with more severe symptoms. Further diagnostic information may be obtained from immunochemical analysis. However, a wide variation in the levels of immunological cross reacting material is observed which, again, does not correlate well with the levels of residual enzyme activity. For example, it is possible to find normal amounts of cross reacting material in patients who are severely deficient in PDH activity.

Elucidation of the genetic basis of PDH deficiency has partly explained the extensive biochemical and immunochemical heterogeneity of this condition. In almost all cases, a defect in the gene for the E1α subunit is responsible. The gene for this subunit has been cloned and localised to Xp22.1. The X chromosome location of the PDH E1α gene partly accounts for the different patterns of presentation of PDH deficiency observed between males and females. In males, all cells express the defective enzyme and the severe metabolic presentation is common. In female patients, the normal allele is expressed in a proportion of the cells, depending on the pattern of X chromosome inactivation, and this may supply sufficient active enzyme to fulfil the needs of most tissues. The threshold for abnormal function in heterozygous females will differ in different tissues, depending on their energy requirements and their ability to use alternative energy substrates, such as fatty acids or amino acids. It appears that this threshold is exceeded in the brain in the majority of heterozygous females as they commonly manifest neurological symptoms, although they are often spared the systemic metabolic acidosis which is so prominent in males.

Cloning of the PDH E1α gene has allowed the identification of the underlying mutation in a number of individual patients. The majority of these are new mutations, although a small number have been described in more than one patient. The wide range of enzyme activities seen presumably reflects the differential effects of specific mutations on the expression, stability, and activity of the mutant protein. A further implication of this mutational heterogeneity is that it is not possible to set up a routine diagnostic service based on screening for one or two common mutations. For diagnosis at the molecular genetic level, it is necessary to examine each patient individually. Previous knowledge of a mutation may assist in prenatal diagnosis for parents who have already borne affected offspring if, for example, the mutation is such that it allows simple detection by generation or removal of a restriction site.

**PDH E1α deficiency in heterozygous females**

Almost all females known to be heterozygous for PDH E1α mutations have manifested the disease and most have died before reaching adulthood. However, the equal number of affected males and females indicates that PDH E1α deficiency is not a fully dominant disease and it is therefore likely that there will be some normal or very mildly affected females. Normally, these will only be detected if they give birth to a more severely affected child and, indeed, a few such cases have been identified. The manifestations of the disease in these females have been restricted to seizures and a variable degree of mental retardation. In one case, the brain appeared normal on CT scan and imaging studies are not indicated as a routine investigation of the mothers of severely affected patients. It is not known if adult females with mild neurological symptoms have consistently raised lactate concentration in cerebrospinal fluid. The striking difference in clinical presentation of females possessing the same mutation can be accounted for by the complicating factor of X inactivation.

In fact, variations in X inactivation patterns appear to be responsible for much of the wide variation in clinical severity in heterozygous females, as mutation analysis has shown that the majority of these females have functionally equivalent frameshift mutations which result in complete deficiency of PDH E1α protein. As a consequence of random X inactivation, some cells will express the X chromosome carrying the normal PDH E1α gene and others will express the X chromosome carrying the mutation. This mosaicism can be shown in cultured fibroblasts from patients with null mutations by immunochemical staining with specific E1α antibodies. The proportion of
cells expressing the normal gene may vary considerably, both in different tissues of the same person and between different persons. Complete PDH deficiency has not been identified in males and present evidence suggests that it is incompatible with fetal development. In heterozygous females, even a relatively small population of cells expressing the normal PDH E1α gene appears to be sufficient to allow survival, at least until birth.

Females present a special problem in diagnosis of PDH deficiency when this is based on measurement of enzyme activity. When the proportion of cells expressing the normal X chromosome exceeds ~75%, enzyme activity and levels of immunoreactive protein cannot be distinguished from the range in normal controls and the diagnosis may be missed. In cultured fibroblasts, which are commonly used for diagnosis, an X inactivation ratio of >3:1 is found in approximately 25% of cultures and in these cases the diagnosis is not excluded by normal enzyme assay results. When the clinical and biochemical features strongly suggest PDH deficiency and the fibroblast enzyme activity is in the normal range, a skewed X inactivation pattern of this order makes it mandatory to screen the PDH E1α gene for a mutation. The diagnosis of PDH E1α deficiency has been established in this way in a number of patients who were initially assessed as normal by enzyme assay.

Prenatal diagnosis

PDH deficiency is a severe disease which results in the death of the great majority of patients before they reach adulthood. Consequently, most of the cases are sporadic and result from a new mutation arising within the germ cells of one of the parents. Although the recurrence risk for PDH E1α deficiency is usually very low, the occurrence of a small number of families with affected sibs, the severity of the disease, and the possibility of germline mosaicism has meant that prenatal diagnosis is almost always requested after diagnosis of an affected child. If the diagnosis is to be based on measurement of enzyme activity, cultured chorionic villus cells are the most suitable fetal material. Repeat assays on living cells, grown under standardised conditions, are needed for reliable diagnosis and chorionic villus cell culture is the optimal means of ensuring that this is achieved before the pregnancy is too advanced. If amniotic cells are used, it usually takes three to four weeks of cell culture before there is sufficient material for the assays.

When the fetus is male, or the enzyme activity in chorionic villus cells is significantly reduced, the diagnosis can be made with confidence. However, extreme skewing of X inactivation patterns presents a major problem when prenatal diagnosis of PDH E1α deficiency in female fetuses is based on enzyme activity measurements in cultured chorionic villus cells. Our experience with chorionic villus cell cultures indicates that not only are many of these clonal, but there may also be a poor correlation between X inactivation and the methylation status at hypervariable X linked loci because the adult pattern of methylation has not been established in these cells. Unless the parental origin of the mutant chromosome in a previously affected child has been determined and it is certain which X chromosome is active in the chorionic villus cells, the diagnosis is not excluded when there is normal enzyme activity and a skewed X inactivation pattern. Clearly, identification of the mutation in an affected child and direct genetic analysis in subsequent pregnancies is the only completely reliable method of prenatal diagnosis.

Treatment

Treatment of PDH deficiency rarely influences the course of the disease. It is usually possible to reverse or minimise systemic lactic acid accumulation by giving a high fat/low carbohydrate “ketogenic” diet, but this does not alleviate the neurological symptoms. In several cases, pathological damage in the brain is present from before birth and many patients do not have significant metabolic problems. There is some evidence that dichloroacetate (which inhibits the specific PDH kinase and thereby activates any residual functioning complex) will also reduce the metabolic disturbance in some patients, but, again, this is rarely accompanied by any objective improvement in neurological performance. A more favourable outcome can be expected in the extremely rare patients with a thiamine responsive form of the disease and, for this reason, a short therapeutic trial of thiamine is worth trying in all cases.

PDH deficiency is a clinically heterogeneous neurometabolic disease in which biochemical abnormalities may be minimal and easily overlooked, especially when the patient has extensive structural defects in the brain. The most common genetic cause of PDH deficiency is mutation in the gene for the E1α subunit. PDH E1α deficiency is an unusual X linked disorder in which males and females are equally affected and most cases are sporadic. Variable manifestation of the disease in heterozygous females appears to be determined largely by differences in the pattern of X inactivation and this also results in considerable difficulties in establishing the diagnosis when this is based on measurements of enzyme activity and immunoreactive protein.

We wish to thank Mrs Nada Al Murani for assistance with the patients’ biochemical studies and Dr J H Cross, Institute of Child Health, University of London, for providing the clinical photograph. This work was supported by a grant from the Wellcome Trust to RMB and SGB.

Pyruvate dehydrogenase deficiency
